Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07163234

Safety of the IPERF Femoral Arterial Cannula in Patients Undergoing Planned Cardiac Surgery With Extracorporeal Circulation Via Femoral Approach

This is a first-in-human, prospective, single-arm, phase I clinical study evaluating the safety of the iPerf femoral arterial cannula in patients undergoing planned cardiac surgery requiring extracorporeal circulation (ECC) via a femoral approach for up to 6 hours. The iPerf device is a dual-lumen arterial cannula designed to provide systemic and lower limb perfusion during ECC, with the goal of reducing the risk of acute limb ischemia. The study will be conducted at a single center in France and will include 15 adult patients. Primary outcomes focus on procedure-related and late adverse events up to 30 days post-surgery. Secondary objectives include assessment of ischemic events, tissue oxygen saturation, and surgeon satisfaction with device handling. The study aims to demonstrate feasibility and safety of the iPerf cannula as an innovative solution for lower limb perfusion during femoral artery cannulation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Jacques Cartier - Ramsay Santé, Massy, France

Loading trial locations.

About this study

This is a first-in-human, prospective, single-arm, phase I clinical study evaluating the safety of the iPerf femoral arterial cannula in patients undergoing planned cardiac surgery requiring extracorporeal circulation (ECC) via a femoral approach for up to 6 hours. The iPerf device is a dual-lumen arterial cannula designed to provide systemic and lower limb perfusion during ECC, with the goal of reducing the risk of acute limb ischemia. The study will be conducted at a single center in France and will include 15 adult patients. Primary outcomes focus on procedure-related and late adverse events up to 30 days post-surgery. Secondary objectives include assessment of ischemic events, tissue oxygen saturation, and surgeon satisfaction with device handling. The study aims to demonstrate feasibility and safety of the iPerf cannula as an innovative solution for lower limb perfusion during femoral artery cannulation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 18 years or older
  • Patient able to understand the study procedures, provide written informed consent, and comply with study procedures
  • Patients with planned cardiac surgery requiring the use of an extracorporeal circulation via a femoral approach for a maximum of 6 hours.
  • Patient affiliated to the social security system

Exclusion criteria

  • Patient weighting less than 45 kg
  • Patient weighting more than 130 kg
  • Patient with common femoral artery diameter less or equal to 6 mm
  • Patient with a stenosis of the aorta, iliac artery, or femoral artery reducing their diameter of more than 50%
  • Patient with previous vascular or endovascular surgery of the iliac or femoral arteries
  • Patient participating in another interventional study
  • Patients with known arterial dissection
  • Patient who is pregnant at the time of enrollment
  • Patients under judicial protection, guardianship or curatorship or subjects deprived of their liberty by judicial or administrative decision

Treatment and study plan

Cardiac surgery

Device

cardiac surgery

Primary outcomes

  1. Safety of the novel IPERF femoral arterial cannula

    Time frame: From enrollment to 30-60 days post surgery

    Per procedure and late adverse events related to the IPERF Femoral Arterial Cannula, up to 30 days after surgery.

Secondary outcomes

  1. Number of patients with at least one ischemic event from cannula installation to decannulation

    Time frame: From enrollment to 30-60 days post surgery

    Number of patients with at least one clinical ischemic event from cannula installation to decannulation defined by clinical observations of the cannulated limb: paleness/ bluish appearance of the leg, oedema, coldness and increased skin recolouring time.

  2. Evolution of Tissue Oxygen Saturation (StO2) versus baseline during femoral cannulation with IPerf™ device between the cannulated and the non-cannulated lower limb.

    Time frame: From enrollment to 30-60 days post surgery

    Evolution of Tissue Oxygen Saturation (StO2) versus baseline the cannulated and non cannulated limb (Ceulemans Heart and Vessels, 2023 and versus baseline during femoral cannulation with IPerf™ device in the cannulated and non-cannulated lower limb by NIRS method

  3. Satisfaction of the surgeon

    Time frame: From enrollment to 30-60 days post surgery

    Satisfaction of the surgeon regarding insertion, positioning, stability, and withdrawal of the device: satisfaction score ≥3 (satisfaction scale: 1- Very dissatisfied, 2- Dissatisfied, 3-Neither dissatisfied or satisfied, 4- Satisfied, 5- Very satisfied)

Study contacts

Contact information is provided by the study sponsor or research team.

Fabien Doguet, Surgeon

CONTACT

[email protected]

+33(0)1 60 13 60 89

Sponsors and collaborators

Lead sponsor

IPERF SAS

Industry

Collaborators

  • European Cardiovascular Research Center

Registry information

Official study title

First-In-Human Study (Phase I) Evaluating the Safety of the IPERF Femoral Arterial Cannula in Patients Undergoing a Planned Cardiac Surgery Requiring the Use of an Extracorporeal Circulation Via a Femoral Approach for a Maximum of 6 Hours

Acronym: FIH IPERF-01

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Sep 9, 2025
Registry last updated
Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.